39 research outputs found
Recommended from our members
Impact of specific functional groups in flavonoids on the modulation of platelet activation
Flavonoids exert innumerable beneficial effects on cardiovascular health including the
reduction of platelet activation, and thereby, thrombosis. Hence, flavonoids are deemed to be a
molecular template for the design of novel therapeutic agents for various diseases including
thrombotic conditions. However, the structure-activity relationships of flavonoids with platelets is
not fully understood. Therefore, this study aims to advance the current knowledge on structure-activity
relationships of flavonoids through a systematic analysis of structurally-related flavones.
Here, we investigated a panel of 16 synthetic flavones containing hydroxy or methoxy groups at
C-7,8 positions on the A-ring, with a phenyl group or its bioisosteres as the B-ring, along with
their thio analogues possessing a sulfur molecule at the 4th carbon position of the C-ring. The
antiplatelet efficacies of these compounds were analysed using human isolated platelets upon
activation with cross-linked collagen-related peptide by optical aggregometry. The results
demonstrate that the hydroxyl groups in flavonoids are important for optimum platelet inhibitory
activities. In addition, the 4-C=O and B ring phenyl groups are less critical for the antiplatelet
activity of these flavonoids. This structure-activity relationships of flavonoids upon the
modulation of platelet function may guide the design, optimisation and development of flavonoid
scaffolds as antiplatelet agents
Mouse models of cancers: opportunities to address heterogeneity of human cancer and evaluate therapeutic strategies
The heterogeneity of human breast cancer has been well described at the morphological, molecular, and genomic levels. This heterogeneity presents one of the greatest obstacles in the effective treatment of breast cancer since the distinct forms of breast cancer that reflect distinct mechanisms of disease will require distinct therapies. Although mouse models of cancer have traditionally been used to simplify the study of human disease, we suggest that there are opportunities to also model the complexity and heterogeneity of human cancer. Here, we illustrate the similarities of mouse models to the human condition in the heterogeneity of both pathologies and gene expression. We then provide an illustration of the potential of gene expression analysis methods when used in conjunction with current treatment options to model individualized therapeutic regimes
The Met oncogene and basal-like breast cancer: another culprit to watch out for?
Recent findings suggest the involvement of the MET oncogene, encoding the tyrosine kinase receptor for hepatocyte growth factor, in the onset and progression of basal-like breast carcinoma. The expression profiles of basal-like tumors - but not those of other breast cancer subtypes - are enriched for gene sets that are coordinately over-represented in transcriptional signatures regulated by Met. Consistently, tissue microarray analyses have revealed that Met immunoreactivity is much higher in basal-like cases of human breast cancer than in other tumor types. Finally, mouse models expressing mutationally activated forms of Met develop a high incidence of mammary tumors, some of which exhibit basal characteristics. The present review summarizes current knowledge on the role and activity of Met in basal-like breast cancer, with a special emphasis on the correlation between this tumor subtype and the cellular hierarchy of the normal mammary gland
A Cell-Based Small Molecule Screening Method for Identifying Inhibitors of Epithelial-Mesenchymal Transition in Carcinoma
Epithelial Mesenchymal Transition (EMT) is a crucial mechanism for carcinoma progression, as it provides routes for in situ carcinoma cells to dissociate and become motile, leading to localized invasion and metastatic spread. Targeting EMT therefore represents an important therapeutic strategy for cancer treatment. The discovery of oncogene addiction in sustaining tumor growth has led to the rapid development of targeted therapeutics. Whilst initially optimized as anti-proliferative agents, it is likely that some of these compounds may inhibit EMT initiation or sustenance, since EMT is also modulated by similar signaling pathways that these compounds were designed to target. We have developed a novel screening assay that can lead to the identification of compounds that can inhibit EMT initiated by growth factor signaling. This assay is designed as a high-content screening assay where both cell growth and cell migration can be analyzed simultaneously via time-course imaging in multi-well plates. Using this assay, we have validated several compounds as viable EMT inhibitors. In particular, we have identified compounds targeting ALK5, MEK, and SRC as potent inhibitors that can interfere with EGF, HGF, and IGF-1 induced EMT signaling. Overall, this EMT screening method provides a foundation for improving the therapeutic value of recently developed compounds in advanced stage carcinoma
The clinical and functional significance of c-Met in breast cancer: a review
This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited.CMH-Y is funded by a Cancer Research UK Clinical Research Fellowship. JLJ is funded by the Breast Cancer Campaign Tissue Bank
Key signaling nodes in mammary gland development and cancer: β-catenin
β-Catenin plays important roles in mammary development and tumorigenesis through its functions in cell adhesion, signal transduction and regulation of cell-context-specific gene expression. Studies in mice have highlighted the critical role of β-catenin signaling for stem cell biology at multiple stages of mammary development. Deregulated β-catenin signaling disturbs stem and progenitor cell dynamics and induces mammary tumors in mice. Recent data showing deregulated β-catenin signaling in metaplastic and basal-type tumors suggest a similar link to reactivated developmental pathways and human breast cancer. The present review will discuss β-catenin as a central transducer of numerous signaling pathways and its role in mammary development and breast cancer